Multicenter phase II study of irinotecan plus weekly bolus 5-FU and high dose l-leucovorin for patients with metastatic colorectal cancer (OGSG 0201).

被引：0
|
作者：
Ishida, H [1 ]
Mishima, H [1 ]
Iwamoto, S [1 ]
Morimoto, T [1 ]
Kato, T [1 ]
Tsujinaka, T [1 ]
Furukawa, Y [1 ]
机构：
[1] Osaka Gastrointestinal Ctr, Chemotherapy Study Grp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3718
引用
收藏
页码：298S / 298S
页数：1
相关论文
共 50 条
  • [41] Phase II study of 5-FU dose-adjusted mFOLFOX7 plus bevacizumab in patients with metastatic colorectal cancer (AJUST study).
    Yakabe, Tomomi
    Denda, Tadamichi
    Morita, Yoshitaka
    Matsuda, Chu
    Kim, Ho Min
    Fujieda, Shinji
    Fukunaga, Mutsumi
    Oba, Koji
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [43] A Randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig
    Goldstein, David
    Gorbounova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Granov, Dmitry A.
    Hossain, Anwar M.
    Blatter, Johannes
    Kaiser, Christopher
    Ma, Doreen
    ONCOLOGY, 2007, 73 (1-2) : 9 - 20
  • [44] A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig R.
    Goldstein, David
    Gorbunova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Melemed, Allen
    Hossain, Anwar
    Granov, Dmitry A.
    ANNALS OF ONCOLOGY, 2006, 17 : 118 - 118
  • [45] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Treatment of advanced colorectal adenocarcinoma with weekly high-dose l-leucovorin and 5-fluorouracil
    Nozue, M
    Isaka, N
    Maruyama, T
    Kawamoto, T
    Seino, K
    Tanagichi, H
    Fukao, K
    ONCOLOGY REPORTS, 2002, 9 (01) : 93 - 96
  • [47] Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
    Lockhart, AC
    Cropp, GF
    Berlin, JD
    Donnelly, E
    Schumaker, RD
    Schaaf, LJ
    Hande, KR
    Fleischer, AC
    Hannah, AL
    Rothenberg, ML
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (02): : 109 - 115
  • [48] Extended phase I study of a weekly schedule of irinotecan (CPT-11), leucovorin and infusional 5-FU as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, U
    Harstrick, A
    Achterrath, W
    Lipp, R
    Mayer, S
    Schöffski, P
    Köhne, CH
    Hossfeld, KD
    Wilke, H
    Seeber, S
    CLINICAL CANCER RESEARCH, 1999, 5 : 3799S - 3799S
  • [49] Phase II study of oxaliplatin, 5-FU and leucovorin in patients with relapsed ovarian cancer
    Thomas, AL
    Osman, A
    Morgan, B
    Khanna, S
    Symonds, RP
    O'Byrne, K
    BRITISH JOURNAL OF CANCER, 2001, 85 : 57 - 57
  • [50] Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases
    Yamaguchi, Tatsuro
    Matsumoto, Hiroshi
    Yasutome, Michiya
    Mori, Takeo
    Takahashi, Keiichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 629 - 635
12345